
|Videos|June 30, 2021
Efficacy, Safety of an Investigational Dose of Semaglutide Injection in Adults With Type 2 Diabetes
Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses the findings around the efficacy and safety of the 2 mg dose of semaglutide for the treatment of type 2 diabetes.
Advertisement
Pharmacy Times interviewed Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, on results from the SUSTAIN FORTE phase 3 clinical trial evaluating an investigational 2 mg dose of semaglutide (Ozempic; Novo Nordisk) injection in adults with type 2 diabetes.
During the discussion, Radin addresses the findings around the efficacy and safety of the 2 mg dose of semaglutide among this patient population.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
mRNA COVID-19 Booster Outperforms Protein-Based Shot on Antibodies, But Both Cut Infections Over 12 Months
2
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
3
Navigating REMS: Challenges, Perspectives, and the Path Forward for Bispecific Antibody Programs
4
Building a Pharmacist-Led Furoscix Workflow From Scratch
5


































































































